


Claims

1. A compound of formula IA



wherein

R^{5A} is $-\text{X}^A-\text{R}^{6A}$ or $-\text{N}(\text{R}^{7A})\text{R}^{8A}$, wherein

X^A is piperidinylene or piperazinylene,

R^{6A} is H, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_4$ alkenyl, $\text{C}_3\text{-C}_4$ alkinyl, $\text{C}_1\text{-C}_4$ (alkoxyalkyl), $\text{C}_1\text{-C}_4$ (carboxyalkyl), a $\text{C}_5\text{-C}_7$ heterocyclic group or phenyl- $\text{C}_1\text{-C}_4$ alkyl;

R^{7A} is amino- $\text{C}_2\text{-C}_4$ alkyl or mono- or di-($\text{C}_1\text{-C}_5$ alkyl)amino- $\text{C}_2\text{-C}_5$ alkyl, and

R^{8A} is H, $\text{C}_1\text{-C}_4$ alkyl or has the meanings as given for R^{7A} ;

X^1 is a divalent group of formula IA' $-(\text{CH}_2)_n-\text{X}^3-(\text{CH}_2)_m-\text{X}^4-\text{N}(\text{R}^{3A})$ wherein

n is zero or 1;


X^3 is CH or N;

(a) X^4 is a direct bond, R^{3A} and R^{4A} together are ethylene and m is 2; or

(b) X^4 is a direct bond, R^{3A} is H, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_3\text{-C}_6$ alkenyl, $\text{C}_3\text{-C}_6$ alkinyl, $\text{C}_7\text{-C}_{10}$ aralkyl or $\text{C}_6\text{-C}_9$ heteroaralkyl, R^{4A} is H and m is 1 or 2 or 3; or

(c) X^4 is $-\text{CH}(\text{R}^{12})-$, R^{3A} is H and R^{4A} and R^{12} together are propylene and m is 1, or ethylene and m is 2;

X^2 is a divalent group of formula IA''



wherein

X^3 is CH or N; and

R^{11} is $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl or $-\text{NR}^{1A}\text{R}^{2A}$, wherein


R^{1A} and R^{2A} independently are $\text{C}_1\text{-C}_4$ alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring; and

R^9 and R^{10} independently are a phenyl or pyridine ring;

and salts thereof.

2. A 2-(2,2-diphenylethylamino)-5-(4-aminocarbonyl-piperidine-1-sulfonyl)-benzoic acid amide or -5-(aminocarbonyl-C₂-C₄alkylcarboxyamino)sulfonyl)-benzoic acid amide, or salt thereof.

3. A compound of formula I




wherein

R¹ and R² independently are C₁-C₄alkyl or, together with the N-atom to which they are attached, represent a 5 to 7 membered heterocyclic ring;

- (a) R³ and R⁴ together are ethylene and m is 2; or
- (b) R³ is H, C₁-C₄alkyl, C₅-C₇cycloalkyl or phenyl-C₁-C₄alkyl, R⁴ is H and m is 1 or 2 or 3;

n is zero or 1; and

R⁵ is -X-R⁶ or -N(R⁷)R⁸, wherein



R⁶ is C₁-C₄alkyl, C₃-C₄alkenyl, C₃-C₄alkinyl, C₁-C₂(alkoxyalkyl), C₁-C₄(carboxyalkyl), a C₅-C₇heterocyclic group or phenyl-C₁-C₄alkyl;


R⁷ is amino-C₂-C₄alkyl or mono- or di-(C₁-C₅alkyl)amino-C₂-C₅alkyl, and

R⁸ is H, C₁-C₄alkyl or has the meanings as given for R⁷;

and salts thereof.


4. A compound according to claim 1 which is {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone, or {2-(2,2-diphenyl-ethylamino)-5-[4-(4-methyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone.

5. A process for the production of a compound of formula IA according to claim 1 which process comprises reacting a compound of formula IIA




wherein X^1 , X^2 , R^9 and R^{10} have the meanings according to claim 1,
with an amine and recovering the obtained compound in free or in salt form.

6. A process for the production of a compound of formula I according to claim 3, which process comprises reacting a compound of formula II



wherein R¹, R², R³, R⁴, m and n have the meanings according to claim 3, with an amine and recovering the obtained compound in free or in salt form.

7. A process for the production of a compound of formula II according to claim 6, which process comprises the steps as outlined in the following scheme:



wherein Hal is halogen, R¹⁵ is C₁-C₄alkyl, and R¹, R², R³, R⁴, m and n are as defined in claim 3.

8. A compound according to claim 1 for use in the treatment of the human or animal body.

9. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment or prevention of a disease or condition in which bradykinin B₁ receptor activation plays a role or is implicated.

10. A method for treating or preventing a disease or condition in which bradykinin B₁ receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1.

11. A pharmaceutical composition for the treatment or prevention of a disease or condition in which bradykinin B₁ receptor activation plays a role or is implicated comprising a compound according to claim 1 and a carrier.

add
B1